^
    Back
    Association details:
    Biomarker:ER mutation
    Cancer:HER2 Negative Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    DGHO 2020
    Title:

    Targeted deep sequencing of circulating tumour DNA reveals mutations in ESR1 and TP53 as the main predictors for progression free and overall survival in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients

    Published date:
    10/10/2020
    Excerpt:
    Subgroup analysis with respect to cancer therapy showed that ESR1 mutations significantly increase mortality risk in patients under combined CDK 4/6 inhibitor-endocrine therapy (HR=14.6 [1.9-110.1]; p=0.009) but not in patients undergoing chemotherapy (p=0.126)....ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patient.